WallStreetZenWallStreetZen

NASDAQ: SAGE
Sage Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

SAGE past revenue growth

How has SAGE's revenue growth performed historically?
Company
1,024.84%
Industry
148.4%
Market
16.96%
SAGE's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
SAGE's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
SAGE's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

SAGE earnings and revenue history

Current Revenue
$86.5M
Current Earnings
-$541.5M
Current Profit Margin
-626.3%

SAGE Return on Equity

Current Company
-58%
Current Industry
-63.5%
Current Market
188%
SAGE's Return on Equity (-58%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when SAGE announces earnings.

SAGE Return on Assets

Current Company
-52.4%
Current Industry
2.9%
SAGE is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

SAGE Return on Capital Employed

Current Company
-67.73%
Current Industry
19.5%
SAGE's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

SAGE vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
SAGE$86.46M-$540.10M-$541.49M-0.86%N/A
TYRA$0.00-$68.78M-$69.13MN/AN/A
ARQT$59.61M-$227.43M-$262.14M+1,517.09%N/A
ZNTL$0.00-$291.40M-$292.19M-100.00%N/A
RLAY$25.55M-$336.70M-$341.97M-88.41%N/A
View Top Biotech Stocks

Sage Therapeutics Earnings & Revenue FAQ

What were SAGE's earnings last quarter?

On Invalid Date, Sage Therapeutics (NASDAQ: SAGE) reported Q4 2023 earnings per share (EPS) of -$0.54, up 78.14% year over year. Total Sage Therapeutics earnings for the quarter were -$32.71 million. In the same quarter last year, Sage Therapeutics's earnings per share (EPS) was -$2.47.

If you're new to stock investing, here's how to buy Sage Therapeutics stock.

What was SAGE's earnings growth in the past year?

As of Q2 2024, Sage Therapeutics's earnings has grown year over year. Sage Therapeutics's earnings in the past year totalled -$541.49 million.

What was SAGE's revenue last quarter?

On Invalid Date, Sage Therapeutics (NASDAQ: SAGE) reported Q4 2023 revenue of $77.97 million up 2,621.54% year over year. In the same quarter last year, Sage Therapeutics's revenue was $2.87 million.

What was SAGE's revenue growth in the past year?

As of Q2 2024, Sage Therapeutics's revenue has grown 1,024.84% year over year. This is 876.43 percentage points higher than the US Biotechnology industry revenue growth rate of 148.4%. Sage Therapeutics's revenue in the past year totalled $86.46 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.